Track Quince Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Quince Therapeutics Inc. Common Stock QNCX · Stock Open Quince Therapeutics Inc. Common Stock in new tab

39.80 USD
EPS
-214.01
P/B
-0.91
ROE
-153.84
Beta
1.33
Target Price
75.00 USD
Loading chart...
Key Metrics
EPS-214.01
Book Value-34.73
Price to Book-0.91
Debt/Equity2.59
% Insiders2.901%
Estimates
Forward P/E-6.78
Forward EPS-4.68
Target Mean Price75.00

DCF valuation

Model fair value for Quince Therapeutics Inc. Common Stock (QNCX)
Result
Sign in to run the valuation for QNCX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Strong buy · mean target 75.00 USD (low 65.00, high 98.00) · as of 12 Nov 2026
Low 65.00
Mean 75.00
High 98.00
Price 39.80
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Quince Therapeutics Inc. Common Stock Logo Quince Therapeutics Inc. Common Stock Analysis (QNCX)

United States Health Care Official Website Stock

Is Quince Therapeutics Inc. Common Stock a good investment? Quince Therapeutics Inc. Common Stock (QNCX) is currently trading at 39.80 USD. Market analysts have a consensus price target of 75.00 USD. This suggests a potential upside from current levels.

Investor FAQ

Does Quince Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Quince Therapeutics Inc. Common Stock?

Quince Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) QNCX
US IRLA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 13, 2026 1:10
June 30, 2026 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion